MULTICENTRE

作品数：75被引量：385H指数：9
导出分析报告
相关领域：医药卫生更多>>
相关作者：张寅更多>>
相关机构：湖南省肿瘤医院中国中医科学院更多>>
相关期刊：《Chinese Journal of Traumatology》《Chinese Journal of Integrative Medicine》《Open Journal of Veterinary Medicine》《Virologica Sinica》更多>>
相关基金：国家自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Efficacy and Safety of Juan Bi Pill with Add-on Methotrexate in Active Rheumatoid Arthritis:A 48-Week,Multicentre,Randomized,Double-Blind,and Placebo-Controlled Trial
《Chinese Journal of Integrative Medicine》2025年第2期99-107,共9页JIA Qing-yun WANG Yi-ru SUN Da-wei MAO Jian-chun XUE Luan GU Xiao-hua YU Xiang PIAO Xue-mei XU Hao LIANG Qian-qian 
Supported by National Natural Science Foundation of China(Nos.81920108032,81822050);State Administration of Traditional Chinese Medicine Young Qi Huang Scholar,Shanghai Science and Technology Innovation Action Plan Medical Innovation Research Project(No.21Y11921400);Innovation Team Project of Scientific Research Project of Traditional Chinese Medicine of Shanghai Health Committee(No.2022CX001);the Program for Innovative Research Team of Ministry of Science and Technology of China(No.2015RA4002);"Innovation Team"Development Projects(No.IRT1270);Shanghai TCM Medical Center of Chronic Disease(No.2022ZZ01009);Shandong Provincial Natural Science Foundation(Nos.ZR2022LZY002 and ZR2021QH230)。
Objective:To explore the efficacy and safety of Juan Bi Pill(JBP)in treatment of active rheumatoid arthritis(RA).Methods:From February 2017 to May 2018,115 participants from 4 centers were randomly divided into JBP gr...
关键词：Chinese medicine Juan Bi Pill METHOTREXATE active rheumatoid arthritis randomized controlled trial 
Danning tablets for the treatment of multiple gallbladder polyps: Study protocol of multicentre, randomised, open-labelled, controlled trial
《iLIVER》2024年第4期56-61,共6页Tian Yang Ming-Da Wang Gui-Lin Xie Xiong-Hua Wang Liu Zheng Li-Min Wang Guang-Fa Xiao Yong-Qing Yang Chao Li Alfred Wei Chieh Kow Feng Shen 
funding from Shanghai Hutchison Pharmaceuticals Company.
Introduction:Gallbladder polyps(GPs)are protrusions of the gallbladder wall into the lumen,and are commonly detected during ultrasound examinations.Traditional management of multiple GPs(MGPs)has been conservative,inc...
关键词：Multiple gallbladder polyps Danning tablets SIZE Lifestyle intervention 
Rationale and design of ProUrokinase in Mild IsChemic strokE(PUMICE):a multicentre,prospective,randomised,open-label,blinded-endpoint controlled trial
《Stroke & Vascular Neurology》2024年第6期715-722,共8页Yunyun Xiong Manjun Hao Yuesong Pan Chunmiao Duan Xueyan Feng Hao Li Na Wu Liyuan Wang Xia Meng Xingquan Zhao Yongjun Wang the PUMICE investigators 
Background and purpose Recombinant human prourokinase(rhPro-UK)is a new generation of specific plasminogen activator,that is non-inferior to alteplase in acute ischemic stroke.We aimed to investigate the efficacy and ...
关键词：acute PROSPECTIVE centre 
Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol Ⅱ(TASTE-2):a multicentre randomised controlled trial被引量：1
《Stroke & Vascular Neurology》2024年第6期730-737,共8页Chunjuan Wang Hong-Qiu Gu Qiang Dong Anding Xu Ning Wang Yi Yang Feng Wang Yongjun Wang 
Simcere Pharmaceutical Group,the Ministry of Science and Technology of the People’s Republic of China(2022YFC2504902,2022YFC2504904);National Natural Science Foundation of China(81801152,92046016);CAMS Innovation Fund for Medical Sciences(2019-I2M 5-029);Beijing Municipal Committee of Science and Technology(Z201100005620010,Z211100002921064).
Background Edaravone dexborneol is believed to be a novel cytoprotective drug,demonstrating a synergistic combination of antioxidative and anti-inflammatory properties in animal models.The Treatment of Acute Ischaemic...
关键词：protective CENTRE RANDOM 
Perioperative sintilimab and neoadjuvant anlotinib plus chemotherapy for resectable non-small-cell lung cancer:a multicentre,open-label,single-arm,phase 2 trial(TD-NeoFOUR trial)
《Signal Transduction and Targeted Therapy》2024年第11期5310-5318,共9页Hongtao Duan Changjian Shao Zhilin Luo Tianhu Wang Liping Tong Honggang Liu Xin Yao Jie Lei Jinbo Zhao Yuan Gao Tao Jiang Xiaolong Yan 
funded by the National Natural Science Foundation of China(Grant No.82173252);the Miaozi Talent Fund of Tangdu Hospital,Air Force Medical University.
This open-label,single-arm,phase 2 trial evaluated the efficacy and safety of neoadjuvant sintilimab combined with anlotinib and chemotherapy,followed by adjuvant sintilimab,for resectable NSCLC.Forty-five patients re...
关键词：CHEMOTHERAPY NEOADJUVANT PHASE 
Reteplase versus alteplase for acute ischaemic stroke within 4.5 hours(RAISE):rationale and design of a multicentre,prospective,randomised,open-label,blinded-endpoint,controlled phase 3 non-inferiority trial
《Stroke & Vascular Neurology》2024年第5期568-573,共6页Shuya Li Hong-Qiu Gu Hongguo Dai Guozhi Lu Yongjun Wang 
National Natural Science Foundation of China(U20A20358);Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2019-I2M 5-029);Beijing Municipal Science&Technology Commission(No.2221100007422050);National Natural Science Foundation of China(U20A20358);Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences(2019-I2M 5-029);Beijing Municipal Science&Technology Commission(No.2221100007422050).
Background and purpose Reteplase is the third generation of alternative thrombolytic agent.We hypothesis that reteplase will be non-inferior to alteplase in achieving excellent functional outcome at 90 days among elig...
关键词：centre ENDPOINT random 
Effectiveness and Safety of Qishen Yiqi Dripping Pill in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention:3-Year Results from a Multicentre Cohort Study被引量：1
《Chinese Journal of Integrative Medicine》2024年第10期877-885,共9页BAI Rui-na GU Feng CHE Qian-zi ZHANG Xuan CAI Ya-jie XI Rui-xi ZHAO Yang GUO Ming DONG Guo-ju GAO Zhu-ye FU Chang-geng WANG Pei-li DU Jian-peng ZHANG Da-wu DUAN Wen-hui LI Li-zhi YANG Qiao-ning SHI Da-zhuo 
Supported by the Traditional Chinese Medicine Public Welfare Scientific Research Project,State Administration of Traditional Chinese Medicine of the People's Republic of China(No.201007001);Fundamental Research Funds for the Central Public Welfare Research Institutes(No.ZZ13-YQ-005 and No.ZZ13-YQ-005-C1)。
Objectives:To evaluate the effectiveness and safety of Qishen Yiqi Dripping Pill(QSYQ)in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods:This multicentre prospective coh...
关键词：Qishen Yiqi Dripping Pill acute coronary syndrome percutaneous coronary intervention primary and secondary endpoint 
First-line penpulimab(an anti-PD1 antibody)and anlotinib(an angiogenesis inhibitor)with nab-paclitaxel/gemcitabine(PAAG)in metastatic pancreatic cancer:a prospective,multicentre,biomolecular exploratory,phase II trial被引量：3
《Signal Transduction and Targeted Therapy》2024年第7期2960-2969,共10页Huizi Sha Fan Tong Jiayao Ni Yi Sun Yahui Zhu Liang Qi Xiaoqin Li Wei Li Yan Yang Qing Gu Xing Zhang Xiaoxuan Wang Chan Zhu Dongsheng Chen Baorui Liu Juan Du 
National Key Research and Development Program of China(2020YFA0713804);the National Natural Science Foundation of China(82272811);Jiangsu Province Key Research and Development Program(BE2023654);Nanjing Jiangbei New Area Key Research and Development Program,Special Fund of Health Science and Technology Development of Nanjing(YKK20080);Fundings for Clinical Trials from the Affiliated Drum Tower Hospital,Medical School of Nanjing University(2023-LCYJ-PY-29).
Metastatic pancreatic cancer(mPC)has a dismal prognosis.Herein,we conducted a prospective,multicentre,single-arm,phase II trial evaluating the efficacy and safety of penpulimab and anlotinib in combination with nab-pa...
关键词：CA724 PROSPECTIVE centre 
Neoadjuvant camrelizumab(an anti-PD-1 antibody)plus chemotherapy or apatinib(a VEGFR-2 inhibitor)for initially unresectable stage II–III non-small-cell lung cancer:a multicentre,two-arm,phase 2 exploratory study被引量：1
《Signal Transduction and Targeted Therapy》2024年第7期3015-3023,共9页Haoran Xia Han Zhang Zheng Ruan Huibiao Zhang Liangdong Sun Hezhong Chen Yongxin Zhou Lele Zhang Dongliang Bian Xinsheng Zhu Jing Zhang Fenghuan Sun Huansha Yu Nan Song Xiaogang Liu Yuming Zhu Haiping Zhang Wenxin He Jian Chen Jie Yang Guohan Chen Shiliang Xie Dongfang Tang Xiaomiao Zhang Liang Duan Deping Zhao Qinchuan Li Peng Zhang Gening Jiang 
supported by the National Natural Science Foundation of China(No.82125001);the Innovation Program of Shanghai Municipal Education Commission(No.2023ZKZD33);the Foundation of Shanghai Pulmonary Hospital(No.FKLY20004 and FKCX2304);the Beijing XiSiKe Clinical Oncology Research Foundation(No.YHR2019-0451);Jiangsu Hengrui Pharmaceuticals Co.,Ltd.We thank all the participants who made the study possible.
This multicentre,two-arm,phase 2 study aimed to explore the efficacy and safety of neoadjuvant camrelizumab plus chemotherapy or apatinib in patients with initially unresectable stage II–III non-small-cell lung cance...
关键词：Surgery CHEMOTHERAPY treatment 
Surgical Management of Perforated Colon Tumours in Yaoundé: A Multicentre Retrospective Review of 30-Day Postoperative Outcome
《Surgical Science》2024年第5期330-341,共12页Eric Patrick Savom Richard II Mbele Colman Tamboh Tankou Mahamat Yannick Ekani Boukar Cédric Paterson Atangana Fred Dikongue Dikongue Daniel Biwole Biwole Guy Aristide Bang Arthur Essomba 
Introduction: Colon cancer is often diagnosed late in our context and there is a high prevalence of complicated forms, this including perforation. The optimal surgical treatment remains controversial. The aim of this ...
关键词：Perforated Colon Cancer Postoperative Morbidity and Mortality COLECTOMY Acute Generalized Peritonitis 
全选清除导出
共8页<12345678>
检索报告 对象比较 聚类工具 使用帮助 返回顶部